GENOA, Italy, August 2, 2018 /PRNewswire/ --
ESAOTE, one of the world leaders in the manufacture of diagnosticultrasound systems and probes on the market for more than 30 years, introduces the new MyLab™X7, MyLab™X6 and MyLab™X5 ultrasound systems. These new ultrasound
(Logo: http://mma.prnewswire.com/media/557501/ESAOTE_Logo.jpg )
(Photo: https://mma.prnewswire.com/media/720815/ESAOTE.jpg )
"The MyLab™X7, MyLab™X6 and MyLab™X5 systems renew and complete Esaote's product range," said Giovanni Altobelli, Ultrasound Product Marketing Manager. "Our goal is to make ultrasound acquisition faster and smarter, bearing in mind the increase in diagnostic confidence, the reliability of clinical performance, and the improvement of daily productivity."
Esaote's MyLab™X7 technology makes it possible to reach better, faster, and more reliable decisions thanks to extremely intuitive usability and ergonomics that meet every need. It is a resilient, green, and movable system with unprecedented image quality, optimally simple interface usage, and significantly faster outputs thanks to the zero-click automation functions.
MyLab™X7, ultrasound imaging beyond efficiency.
The new MyLab™X6 makes the clinical workflow so efficient and smooth that it not only increases productivity but also empowers all clinical performances. Fast response and easy interface usage also adapt flawlessly to all clinical needs, providing comfort and flexibility. MyLab™X6, ultrasound imaging beyond flexibility.
With Esaote's new MyLab™X5, which is so smart and simple, you will no longer need to worry about time-consuming adjustments. Zero-click automation helps and speeds up any assessments and the enhanced image quality makes it possible to deliver them confidently and with the utmost precision. MyLab™X5, ultrasound imaging beyond ease.
Developed to provide high-quality ultrasound technology to hospitals, clinics, and private practices, MyLab™X7, MyLab™X6, and MyLab™X5 offer advanced clinical tools and large probe portfolios with zero-click automation. For more information, visit our esaote.com website at: MyLab™X7, MyLab™X6, MyLab™X5
Karl-Heinz Lumpi, Chief Executive Officer of Esaote said: "Today, efficiency and reliability are the most demanding challenges, especially in the clinical world. The three new MyLab™ ultrasound systems are the smartest and fastest answers to customers' diagnostic and clinical needs in everyday practice."
The MyLab™X7, MyLab™X6, and MyLab™X5 will be presented at JFR 2018 in Paris, October 12 to 15, Palais des Congrès, BOOTH 1N01 - Niveau 1 - Hall Neuilly.
About Esaote: The Esaote Group is a leader in the biomedical equipment sector. In particular, Esaote is recognized as one of the Top 10 diagnostic imaging companies in the world (source: VPG Market Research) in the areas of ultrasound, dedicated MRI and software for managing the diagnostic process. Headquartered in Genoa, Italy, the Group has its production and research units in Italy (Genoa and Florence) as well as in the Netherlands (Maastricht) and it is active in around 80 countries in the world. The Esaote Group recorded a consolidated turnover of around €250 million in 2017, 70% of which was generated on international markets. The Group employs about 1,150 individuals, 20% of whom work in research and development, a sector in which the company invests around 9% of its total turnover. Information on Esaote and its products is available at http://www.esaote.com
Follow us on LinkedIn (Esaote), YouTube (esaotegroup), or Vimeo (Esaote)
© Copyright Esaote 2018
Technology and features are system/configuration dependent. Specifications are subject to change without notice. Information might refer to products or modalities not yet approved in all countries. For further details, please contact your Esaote sales representative.
SOURCE Esaote S.p.A.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All